Quick Answer
PLUS THERAPEUTICS, INC. reported Total Revenue of $5.21 million for fiscal year 2025.
PLUS THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $5.21M -10.5% |
$5.82M +18.5% |
$4.91M | — | — | — |
| Revenue (ASC 606) | — | — | — | — | — | — |
| Net Income | -$22.39M -72.5% |
-$12.98M +2.5% |
-$13.32M +34.3% |
-$20.27M -51.3% |
-$13.40M -62.6% |
-$8.24M +24.3% |
| Diluted EPS | -$0.29 +87.6% |
-$2.34 +44.8% |
-$4.24 +63.4% |
-$11.58 -943.2% |
-$1.11 | — |
| Total Assets | $16.32M +146.1% |
$6.63M -41.8% |
$11.39M -52.3% |
$23.87M +8.6% |
$21.98M +81.6% |
$12.11M -47.9% |
| Cash and Equivalents | $4.26M +5500.0% |
$76.0K -99.1% |
$8.55M -52.8% |
$18.12M -1.5% |
$18.40M +120.5% |
$8.35M -52.4% |
| Long-Term Debt | — | — | — | $3.79M -24.4% |
$5.00M | — |
| Stockholders Equity | $4.00M +144.7% |
-$8.95M -563.9% |
-$1.35M -120.9% |
$6.45M -40.5% |
$10.84M +257.5% |
$3.03M +161.3% |
| R&D Expense | $8.38M -20.8% |
$10.58M +9.2% |
$9.69M -0.1% |
$9.70M | — | $2.70M -49.7% |
| Operating Income | -$15.30M -4.1% |
-$14.70M -10.3% |
-$13.32M +32.4% |
-$19.71M -57.8% |
-$12.49M -30.3% |
-$9.58M -162.1% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 138.68M +2251.9% |
5.90M -84.2% |
37.40M +1569.6% |
2.24M -85.6% |
15.51M +129.8% |
6.75M +73.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.40M | -4.1% | +0.5% |
| Revenue (ASC 606) | March 31, 2019 | $703.0K | -3.8% | -18.1% |
| Net Income | September 30, 2025 | -$4.42M | -53.9% | -185.9% |
| Diluted EPS | September 30, 2025 | -$0.04 | +89.2% | -300.0% |
| Total Assets | September 30, 2025 | $18.67M | +167.6% | +80.4% |
| Cash and Equivalents | September 30, 2025 | $13.29M | +986.6% | +495.1% |
| Long-Term Debt | December 31, 2022 | $3.79M | -24.4% | -7.8% |
| Stockholders Equity | September 30, 2025 | $5.05M | +197.7% | +66.6% |
| R&D Expense | September 30, 2025 | $2.44M | -14.8% | +95.5% |
| Operating Income | September 30, 2025 | -$4.48M | -18.0% | -191.4% |
| Gross Profit | September 30, 2018 | $230.0K | +1250.0% | +666.7% |
| Shares Outstanding | September 30, 2025 | 131.61M | +2132.0% | +42.8% |
- PLUS THERAPEUTICS, INC. reported Total Revenue of $5.21 million for fiscal year 2025.
- PLUS THERAPEUTICS, INC. showed a decrease of -10.5% in Total Revenue compared to the prior fiscal year.
- PLUS THERAPEUTICS, INC. reported Revenue (ASC 606) of $3.67 million for fiscal year 2018.
- PLUS THERAPEUTICS, INC. showed an increase of +36.5% in Revenue (ASC 606) compared to the prior fiscal year.
- PLUS THERAPEUTICS, INC. reported Net Income of -$22.39 million for fiscal year 2025.
- PLUS THERAPEUTICS, INC. showed a decrease of -72.5% in Net Income compared to the prior fiscal year.
- PLUS THERAPEUTICS, INC. reported Diluted EPS of $0.29 per share (loss) for fiscal year 2025.
- PLUS THERAPEUTICS, INC. showed an increase of +87.6% in Diluted EPS compared to the prior fiscal year.
- PLUS THERAPEUTICS, INC. reported Total Assets of $16.32 million for fiscal year 2025.
- PLUS THERAPEUTICS, INC. showed an increase of +146.1% in Total Assets compared to the prior fiscal year.
- PLUS THERAPEUTICS, INC. reported Cash and Equivalents of $4.26 million for fiscal year 2025.
- PLUS THERAPEUTICS, INC. showed an increase of +5500.0% in Cash and Equivalents compared to the prior fiscal year.
- PLUS THERAPEUTICS, INC. reported Long-Term Debt of $3.79 million for fiscal year 2022.
- PLUS THERAPEUTICS, INC. showed a decrease of -24.4% in Long-Term Debt compared to the prior fiscal year.
- PLUS THERAPEUTICS, INC. reported Stockholders Equity of $4.00 million for fiscal year 2025.
- PLUS THERAPEUTICS, INC. showed an increase of +144.7% in Stockholders Equity compared to the prior fiscal year.
- PLUS THERAPEUTICS, INC. reported R&D Expense of $8.38 million for fiscal year 2025.
- PLUS THERAPEUTICS, INC. showed a decrease of -20.8% in R&D Expense compared to the prior fiscal year.
- PLUS THERAPEUTICS, INC. reported Operating Income of -$15.30 million for fiscal year 2025.
- PLUS THERAPEUTICS, INC. showed a decrease of -4.1% in Operating Income compared to the prior fiscal year.
- PLUS THERAPEUTICS, INC. reported Gross Profit of $146.0 thousand for fiscal year 2017.
- PLUS THERAPEUTICS, INC. showed a decrease of -92.5% in Gross Profit compared to the prior fiscal year.
- PLUS THERAPEUTICS, INC. reported Shares Outstanding of 138.68 million shares for fiscal year 2025.
- PLUS THERAPEUTICS, INC. showed an increase of +2251.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: